Saltroad raises £1.5M for AI speech therapy
Saltroad raised £1.5M and acquired Ogma to scale AI-supported speech therapy for children. This draft is marked review-needed because source details were limited.
Speech therapy is a capacity-constrained area where AI support could matter if it is designed carefully.
What happened
Saltroad raised £1.5M and acquired AI platform Ogma to help scale speech therapy for children.
This item should be reviewed before publishing because the initial pull only verified the headline-level details, not the full company and investor context.
Why it matters
Speech therapy can be difficult to access quickly, especially for children who need consistent support. AI tools could help clinicians extend care, structure practice and make support more available between sessions.
This is not about replacing specialist therapists. The useful angle is whether software can help scale access to care without lowering quality.
The bigger picture
Healthtech AI is moving beyond diagnosis and admin into care delivery support. The safest and most useful products may be the ones that help professionals reach more patients, rather than trying to automate care entirely.
Saltroad’s move fits that broader pattern of AI being used as a support layer in constrained healthcare workflows.